China's Antengene in deal for Celgene cancer candidate

Antengene Corp. (Shanghai, China) said it gained Greater China rights to oncology candidate CC-223 from Celgene Corp. (NASDAQ:CELG). Celgene received an undisclosed equity stake in Antengene, and took a board seat.

Antengene will be responsible for local development and commercialization of CC-223. Founder and Chairman Jay Mei said the company intends to begin Phase II/III trials in Greater China of the candidate to treat hepatocellular carcinoma (HCC). Mei was an executive director of clinical development in hematology and oncology at Celgene...